Business Context and Reporting Period
Company: Biospherics Incorporated (Note: Metadata listed "Dominari Holdings Inc." but filing text confirms Biospherics Incorporated).
Filing Type: Form 10-Q (Quarterly Report).
Period: Three months ended March 31, 2001.
Operations: The Company operates in three segments: InfoSpherix Government, InfoSpherix Commercial, and BioSpherix. InfoSpherix provides information and telecommunications services, while BioSpherix focuses on biotechnology products including tagatose and FlyCracker.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Revenue | $5,217,727 | $5,253,517 |
| Net (Loss) Income | $(157,077) | $1,018,377 |
| Operating Income (Loss) | $(218,948) | $1,021,010 |
| EPS (Diluted) | $(0.01) | $0.09 |
| Cash and Equivalents | $5,039,076 | $4,831,991 |
| Working Capital | $6,203,000 | $6,358,000 (Dec 31, 2000) |
| Debt (Bank Line) | $0 | $386,274 (Dec 31, 2000) |
Cash Flow: Net cash provided by operating activities was $456,772. Net cash used in investing activities was $182,686. Net cash used in financing activities was $784,876.
Material Changes vs. Prior Period
- Profitability Reversal: The Company shifted from a net income of $1.02 million in Q1 2000 to a net loss of $157,000 in Q1 2001, despite relatively flat total revenue.
- Segment Performance:
- InfoSpherix Government: Revenue doubled to $4.48 million (up $2.2 million) due to new contracts and a $1.3 million settlement from the GSA regarding a Department of Labor case. However, operating losses remained near $222,000 due to associated settlement costs.
- InfoSpherix Commercial: Revenue plummeted 76% to $737,000 from $3.02 million, driven by the conclusion of a significant short-term pharmaceutical contract in the prior year.
- BioSpherix: Revenue remained negligible ($2,000) with consistent operating losses around $157,000.
- Expense Increases: Direct contract costs rose 34% ($1.0 million) primarily due to the ARB settlement. SG&A expenses increased by $172,000 due to increased marketing for InfoSpherix and FlyCracker.
- Liquidity: The Company paid down its entire bank line of credit balance ($386,274) using cash surpluses. Cash and cash equivalents decreased by $511,000 during the quarter.
Guidance, Outlook, and Risks
- Tagatose Commercialization: An Expert Panel determined tagatose is "Generally Recognized As Safe" (GRAS). Arla Foods (licensing partner) is notifying the FDA. Royalties are anticipated to begin in late 2002.
- Contract Outlook: Management anticipates that options on major government contracts will be exercised, extending them beyond 2001.
- Liquidity Position: The Company has a $1.5 million line of credit with Bank of America, currently unused. Management believes it has adequate funds to meet obligations for the remainder of 2001 even if the line is not renewed upon expiration in June 2001.
- Risks: Commercial revenues are subject to substantial variation due to short-term contract durations. Forward-looking statements regarding tagatose commercialization and contract renewals involve uncertainties.
Investor Verification Checklist
- Settlement Impact: Verify the net financial impact of the $1.3 million GSA settlement versus the $1.7 million expense recognized in Q1 2001.
- Commercial Contract Pipeline: Assess the replacement strategy for the lost $2.3 million in commercial revenue from the expired pharmaceutical contract.
- Tagatose Timeline: Monitor FDA notification status and Arla Foods' commercialization progress to validate the 2002 royalty start date.
- Debt Covenants: Confirm continued compliance with Bank of America covenants (tangible net worth and cash flow coverage) as the line of credit expires in June 2001.
- Accrued Liabilities: Review the significant increase in accrued salaries and benefits (from $974k to $2.16M) to understand the timing of cash outflows.